Glenmark has dropped the price of its trastuzumab biosimilar by over 70% in India. Scrip talks to experts on what that may mean for the competition and also spotlights action around other HER2-directed therapies, including the impending arrival of blockbuster ADC Enhertu.

Senior Parexel executives tell Scrip that disruptions resulting from the Ukraine war and constraints in the US given the backlog in clinical care there could channel more trials to the Asia-Pacific region. They also discuss how things are moving in China, a market where the CRO has long-standing experience, the "conducive" ecosystem in India and issues around trial diversity.

A roundup of key regulatory and policy developments in the Asia-Pacific in the first half of the year reveals broad developments across the region's diverse markets, although there seemed to be a common thread - a renewed focus on infectious diseases amid the lingering impact of the pandemic and the emergence of new threats.